Version: 1.0.0 | Published: 24 Sep 2026 | Updated: 0 days ago
Documentation
Description:
The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Prognostic and Natural History Study (PNHS) is an open-label, prospective, multicentre, cohort study linked to a variety of European Parent Cohorts.
AMYPAD PNHS aims to improve disease modelling efforts and individualized risk stratification within the context of Alzheimer"s disease through the additional collection of amyloid burden using positron emission tomography (PET) imaging.
The harmonised AMYPAD PNHS dataset integrates information from 10 Parent Cohorts: ALFA+, AMYPAD DPMS, DELCODE, EMIF-AD (60++), EMIF-AD (90+), EPAD LCS, FACEHBI, FPACK, Microbiota, and UCL-2010-412, comprising a total of 3368 participants. Of these, 1620 underwent a baseline amyloid PET, including visual reads and the Centiloid quantification (1476 subjects) among other metrics. Moreover, 888 participants have (at least) one follow-up PET scan, 884 of whom have Centiloid quantification. The participant’s demographic data, clinical outcomes (e.g., cognition), disease biomarkers (imaging and CSF), risk factors (e.g., genetics and environmental), and other relevant variables are included in the dataset. This updated version of the AMYPAD dataset adds computed polygenic risk scores from harmonised genotype array data, a comprehensive set of imaging-derived endophenotypes from various MRI processing pipelines and corrections to selected cognition-related scores.
Please see DOI: 10.5281/zenodo.21309778 to see a document outlining the changes and updates made on the AMYPAD PNHS dataset from v202306 to 202606.
Coverage
Spatial:
US
Follow Up:
Unknown
Provenance
Temporal
Accrual Periodicity:
Static
Start Date:
01 January 2026
Time Lag:
Not applicable
Accessibility
Access
Access Rights:
See dataset for details. Access data at:
Usage
Resource Creators:
AMYPAD
Observations
Statistical Population
Population Description
Population Size
Measured Property
Observation Date
Persons
3266
Count
01 January 2026